Functional characterization and quality of life in patients with Parkinson’s disease in a third level hospital Bogotá D.C., Colombia
DOI:
https://doi.org/10.28957/rcmfr.v29n2a3Keywords:
Parkinson’s Disease, Mobility Limitation, Quality of Life (MeSH).Abstract
Introduction. Parkinson’s disease is considered the second neurodegenerative disease, generating motor and neuropsychiatric disability; It is a multifactorial disease, bradykinesia, the cardinal symptom followed by tremor, stiffness and postural instability; which impacts the functionality and quality of life of the patient. Epidemiological studies show that the prevalence of this disease in Colombia is 4.7 affected per thousand people over 50 years. For this reason it is necessary to quantify the commitment and care needs of these patients.Objectives. The objective was the functional characterization and quality of life of 60 patients with Parkinson’s disease in a third level hospital, Bogotá DC. In the period from November 2015 to June 2016.
Materials and methods. Cross-sectional study with an analytical component, 60 patients met the inclusion criteria, the PDQ-39 quality of life questionnaire and the functionality scale for patients with Parkinson’s disease MDS-UPDRS were applied.
Results: they showed 55% (33) men and 45% (27) women, with an average of 67 years, with a range between 40-84 years. The greatest deterioration was evident in the domains of mobility, activities of daily living, cognition and bodily discomfort.
Discussion and conclusions. In patients with Parkinson’s disease of a level III hospital. Bogota Colombia. There is a moderate commitment in the quality of life, in the domains of mobility and activities of daily life. In the functional aspect, clinically a motor commitment in the aspects of bradykinesia, gait and rigidity was evident.
References
1 Kakklar AK, Dahiya N. Management of Parkinson’s disease: Current and future pharmacotherapy. Eur J Pharmacol. 2015;750:74–81. Disponible en: https://doi.org/10.1016/j.ejphar.2015.01.030.
2 Castro-Toro A, Buritica OF. Enfermedad de Parkinson: criterios diagnósticos, factores de riesgo y de progresión, y escalas de valora- ción del estadio clínico. Acta Neurol Colomb. 2014;30(4):300-6.
3 Mullin S, Schapira AH. Pathogenic mechanisms of neurodegeneration in parkinson disease. Neurol Clin. 2015;33(1):1-17. Disponible en: https://doi.org/10.1016/j.ncl.2014.09.010.
4 Pradilla G, Vega BE, León-Sarmiento FE. Es- tudio neuroepidemiologico nacional (EPINEURO) colombiano. Rev Panam Sa- lud Publica 2003;14(2):104-10.
5 Arango M, Molina R. Consideraciones anestésicas en la enfermedad de Parkinson. Rev. Colomb. Anestesiol. 2008;36(3):207-15.
6 Sánchez JL, Buriticá O, Pineda D, Uribe CS, Palacio LG. Prevalence of Pa rkinson’s disease and Parkinsonism in a Colombian population using the capture-recapture method. Int J Neurosci. 2004;114(2):175-82. Disponible en: https://doi.org/10.1080/00207450490269444.
7 Garcia-Ruiz PJ, Chaudhuri KR, Martinez- Martin P. Non-motor symptoms of Parkinson’s disease A review… from the past. J Neurol Sci. 2014;338(1-2):30-3. Disponible en: https://doi.org/10.1016/j.jns.2014.01.002.
8 Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson’s disease. Parkinso- nism Relat Disord. 2010;16(2):79-84. Dispo- nible en: https://doi.org/10.1016/j. parkreldis.2009.08.007.
9 Nutt JG, Wooten GF. Clinical practice. Diag- nosis and initial management of Parkinson’s disease. N Engl J Med. 2005;353(10):1021-7. Disponible en: https://doi.org/10.1056/ NEJMcp043908.
10 Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. Am Fam Physician. 2013 ;87(4):267-73.
11 Palacios E, Silva MA. Síntomas no motores en la enfermedad de Parkinson, ¿relación con la lateralidad al inicio de la enfermedad?. Acta Neurol Colomb. 2015; 31(3):261-266.
12 Diazgranados-Sánchez JA, Chan-Guevara L, Gómez-Betancourt LF, Lozano-Arango AF, Ramírez M. Descripción de la población de pacientes con enfermedad de Parkinson en un centro médico neurológico en la ciudad de Cali, Colombia. Acta Neurol Colomb. 2011;27(4):205-10.
13 Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Move- ment Disorder Society-sponsored revision of the United Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing Plan. Mov Disord. 2007;22(1):41-7. Disponible en: https://doi.org/10.1002/mds.21198.
14 Mar tínez-Mar tin P, Forjaz MJ. Metric Attributes of the Unified Parkinson’s Disease Rating Scale 3.0 Battery: Part I, Feasibility, Scaling Assumptions, Reliability, and Precision. Mov Disord. 2006;21(8):1182-8. Disponible en: https://doi.org/10.1002/ mds.20916.
15 Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Move- ment Disorder Society-Sponsored Revision of the Uni?ed Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. Mov Disord. 2008;23(15):2129-70. Disponible en: https://doi.org/10.1002/mds.22340.
16 Martínez-Martin P, Rodriguez-Blazquez C, Al- varez-Sanchez M, Arakaki T, Bergareche- Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society–Uni?ed Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013;260(1):228-36. Disponible en: https://doi.org/10.1007/s00415-012-6624-1.
17 Rodriguez-Violante M, Cervantes-Arriaga A. La escala unificada de la enfermedad de Parkinson modificada por la Sociedad de Trastornos del Movimiento (MDS-UPDRS): aplicación clínica e investigación. Arch Neurocien (Mex). 2014 ;19(3):157-63.
18 Echeverry-Diaz J. Validación de la nueva ver- sión de la escala unificada para la evalua- ción de la enfermedad de Pa rkinson (MDS-UPDRS) en español. Resultados de la fase I: (validación lingüística) [tesis]. Bogo- tá D.C.: Facultad de Medicina y Ciencias de la Salud; 2011.
19 Martínez-Martín P, Frades-Payo B. Quality of life in Parkinson’s disease: validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol. 1998;245(Suppl 1):S34-8. Disponi- ble en: https://doi.org/10.10 07 / PL00007737.
20 Arango-Hoyos GP, Bolaños-Roldan AM, Fernández-Hurtado BE. Calidad de vida y discapacidad en personas con enfermedad de Parkinson de la ciudad de Cali 2011 [te- sis]. Manizales: Facultad de Salud, Universi- dad Autónoma de Manizales; 2012.
21 Skor vaneck M, Rosenberger J, Minar M, Grofik M, Han V, Groothoff JW, et al. Relationship between the non-motor items of the MDS–UPDRS and Quality of Life in patients with Parkinson’s disease. J Neurol Sci. 2015;353(1-2):87-9. Disponible en: https://doi.org/10.1016/j.jns.2015.04.013.
22 Berganzo K, Tijero B, González-Eizaguirrea A, Sommeb J, Lezcanoa E, Gabilondo, I, et al. Síntomas no motores y motores en la en- fermedad de Parkinson y su relación con la calidad de vida y los distintos subgrupos clí- nicos. Neurologia. 2016;31(9):585-91. Dispo- nible en: https://doi.org/10.1016 / j.nrl.2014.10.010.
23 Goldman JG. Stebbins GT, Leung V, Tilley BC, Goetz CG. Relationships among cognitive impairment, sleep, and fatigue in Parkinson’s disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014;20(11): 1135-9. Disponible en: https://doi.org/10.1016/j.parkreldis.2014.08.001.
24 Rodríguez-Violante M, Cervantes-Arriaga A, Morales-Briceño H, Neri-Nani GA, Estrada- Bellmann I, Millán-Cepeda MR, et al. Estudio multicéntrico de evaluación de la sintomatología no motora a través de la Es- cala unificada de la enfermedad de Parkin- son de la Sociedad de Trastornos del Movimiento (MDS-UPDRS). Rev Mex Neuroci. 2014;15(4):201-6.
2 Castro-Toro A, Buritica OF. Enfermedad de Parkinson: criterios diagnósticos, factores de riesgo y de progresión, y escalas de valora- ción del estadio clínico. Acta Neurol Colomb. 2014;30(4):300-6.
3 Mullin S, Schapira AH. Pathogenic mechanisms of neurodegeneration in parkinson disease. Neurol Clin. 2015;33(1):1-17. Disponible en: https://doi.org/10.1016/j.ncl.2014.09.010.
4 Pradilla G, Vega BE, León-Sarmiento FE. Es- tudio neuroepidemiologico nacional (EPINEURO) colombiano. Rev Panam Sa- lud Publica 2003;14(2):104-10.
5 Arango M, Molina R. Consideraciones anestésicas en la enfermedad de Parkinson. Rev. Colomb. Anestesiol. 2008;36(3):207-15.
6 Sánchez JL, Buriticá O, Pineda D, Uribe CS, Palacio LG. Prevalence of Pa rkinson’s disease and Parkinsonism in a Colombian population using the capture-recapture method. Int J Neurosci. 2004;114(2):175-82. Disponible en: https://doi.org/10.1080/00207450490269444.
7 Garcia-Ruiz PJ, Chaudhuri KR, Martinez- Martin P. Non-motor symptoms of Parkinson’s disease A review… from the past. J Neurol Sci. 2014;338(1-2):30-3. Disponible en: https://doi.org/10.1016/j.jns.2014.01.002.
8 Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson’s disease. Parkinso- nism Relat Disord. 2010;16(2):79-84. Dispo- nible en: https://doi.org/10.1016/j. parkreldis.2009.08.007.
9 Nutt JG, Wooten GF. Clinical practice. Diag- nosis and initial management of Parkinson’s disease. N Engl J Med. 2005;353(10):1021-7. Disponible en: https://doi.org/10.1056/ NEJMcp043908.
10 Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. Am Fam Physician. 2013 ;87(4):267-73.
11 Palacios E, Silva MA. Síntomas no motores en la enfermedad de Parkinson, ¿relación con la lateralidad al inicio de la enfermedad?. Acta Neurol Colomb. 2015; 31(3):261-266.
12 Diazgranados-Sánchez JA, Chan-Guevara L, Gómez-Betancourt LF, Lozano-Arango AF, Ramírez M. Descripción de la población de pacientes con enfermedad de Parkinson en un centro médico neurológico en la ciudad de Cali, Colombia. Acta Neurol Colomb. 2011;27(4):205-10.
13 Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Move- ment Disorder Society-sponsored revision of the United Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing Plan. Mov Disord. 2007;22(1):41-7. Disponible en: https://doi.org/10.1002/mds.21198.
14 Mar tínez-Mar tin P, Forjaz MJ. Metric Attributes of the Unified Parkinson’s Disease Rating Scale 3.0 Battery: Part I, Feasibility, Scaling Assumptions, Reliability, and Precision. Mov Disord. 2006;21(8):1182-8. Disponible en: https://doi.org/10.1002/ mds.20916.
15 Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Move- ment Disorder Society-Sponsored Revision of the Uni?ed Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. Mov Disord. 2008;23(15):2129-70. Disponible en: https://doi.org/10.1002/mds.22340.
16 Martínez-Martin P, Rodriguez-Blazquez C, Al- varez-Sanchez M, Arakaki T, Bergareche- Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society–Uni?ed Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013;260(1):228-36. Disponible en: https://doi.org/10.1007/s00415-012-6624-1.
17 Rodriguez-Violante M, Cervantes-Arriaga A. La escala unificada de la enfermedad de Parkinson modificada por la Sociedad de Trastornos del Movimiento (MDS-UPDRS): aplicación clínica e investigación. Arch Neurocien (Mex). 2014 ;19(3):157-63.
18 Echeverry-Diaz J. Validación de la nueva ver- sión de la escala unificada para la evalua- ción de la enfermedad de Pa rkinson (MDS-UPDRS) en español. Resultados de la fase I: (validación lingüística) [tesis]. Bogo- tá D.C.: Facultad de Medicina y Ciencias de la Salud; 2011.
19 Martínez-Martín P, Frades-Payo B. Quality of life in Parkinson’s disease: validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol. 1998;245(Suppl 1):S34-8. Disponi- ble en: https://doi.org/10.10 07 / PL00007737.
20 Arango-Hoyos GP, Bolaños-Roldan AM, Fernández-Hurtado BE. Calidad de vida y discapacidad en personas con enfermedad de Parkinson de la ciudad de Cali 2011 [te- sis]. Manizales: Facultad de Salud, Universi- dad Autónoma de Manizales; 2012.
21 Skor vaneck M, Rosenberger J, Minar M, Grofik M, Han V, Groothoff JW, et al. Relationship between the non-motor items of the MDS–UPDRS and Quality of Life in patients with Parkinson’s disease. J Neurol Sci. 2015;353(1-2):87-9. Disponible en: https://doi.org/10.1016/j.jns.2015.04.013.
22 Berganzo K, Tijero B, González-Eizaguirrea A, Sommeb J, Lezcanoa E, Gabilondo, I, et al. Síntomas no motores y motores en la en- fermedad de Parkinson y su relación con la calidad de vida y los distintos subgrupos clí- nicos. Neurologia. 2016;31(9):585-91. Dispo- nible en: https://doi.org/10.1016 / j.nrl.2014.10.010.
23 Goldman JG. Stebbins GT, Leung V, Tilley BC, Goetz CG. Relationships among cognitive impairment, sleep, and fatigue in Parkinson’s disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014;20(11): 1135-9. Disponible en: https://doi.org/10.1016/j.parkreldis.2014.08.001.
24 Rodríguez-Violante M, Cervantes-Arriaga A, Morales-Briceño H, Neri-Nani GA, Estrada- Bellmann I, Millán-Cepeda MR, et al. Estudio multicéntrico de evaluación de la sintomatología no motora a través de la Es- cala unificada de la enfermedad de Parkin- son de la Sociedad de Trastornos del Movimiento (MDS-UPDRS). Rev Mex Neuroci. 2014;15(4):201-6.
How to Cite
1.
Avendaño-Avendaño SB, Bernal-Pacheco O, Esquivia-Pájaro CT. Functional characterization and quality of life in patients with Parkinson’s disease in a third level hospital Bogotá D.C., Colombia. Rev. Colomb. Med. Fis. Rehabil. [Internet]. 2020 Apr. 2 [cited 2024 May 16];29(2):93-102. Available from: https://revistacmfr.org/index.php/rcmfr/article/view/209
Downloads
Download data is not yet available.
Downloads
Published
2020-04-02
Issue
Section
Original articles
